Faron Pharmaceuticals Oy. Stock Analysis FARN.L

Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company, which engages in the development of drugs to treat acute respiratory distress syndrome. The company is headquartered in Turku, Lansi-Suomen and currently employs 33 full-time employees. The company went IPO on 2015-11-17. The firm has three drug candidates all based on mastering immune modulation and, as a result, tackling unmet needs in cancer, preventing organ damage and treating blood count abnormalities. The firm's goal is to build future immunotherapy, i.e., to bring new treatments to patients by affecting the immune system. Faron’s drug candidate, Traumakine, is a drug developed by the Company to prevent multi-organ damage and excessive inflammatory responses. Another drug candidate, Haematokine, promotes the expansion of bone marrow stem cells. The company is being developed, e.g., for the treatment of chemotherapyinduced neutropenia (CIN). In neutropenia patients have less blood cells called neutrophils than normal due to cancer treatment.